Monday , May 23 2022

Factors & # 39; biomarkers and clinical risk for atrial fibrillation – Medical News



[ad_1]

Clinics: seniors, men, high BMI. Biomarkers: natriuretika peptide of mind and factor of the fibroblast growth 23

University & # 39; Birmingham

Researchers at the University of Birmingham found two biomarkers that can be used to identify atrial fibrillation in & # 39; three patients' clinical risk. "

Atrial fibrillation is the most common disorder of heart rhythm and affects about 1.6 million people in the UK. Those with & # 39; atrial fibrillation may be aware of & # 39; remarkable heart palpitations, when their heart feels currently beat, beat or beat b & # 39; irregular manner. Sometimes atrial fibrillation causes no symptoms and a person who does not know completely that his heart rhythm is irregular.

Now, scientists have identified that patients have an increased risk of atrial fibrillation if they have three "Clinical risk":

  1. Elderly
  2. men
  3. high body mass index

These patients, scientists say, can be screened for atrial fibrillation by testing their blood to see if they have high levels of & # 39; two biomarkers:

  1. Natriuretika brain peptide (BNP)
  2. Protein regulates phosphate factor called fibroblast factor 23 (FGF-23).

The research was made by scientists from the Institute of Cardiovascular Sciences and Cancer Institute and the genomics of the Faculty of Medical Sciences and Dental Sciences & # 39; University & # 39; Birmingham and published in the European Heart Journal.

The first author, Dr. Winnie Chua, said: "Persons with & # 39; atrial fibrillation are much more likely to develop blood clots and suffer from strokes.

To prevent strokes is important to take anticoagulant drugs to prevent blood clotting. However, very often atrial fibrillation is diagnosed only after a patient has suffered a stroke.

"It is important that patients in & # 39; risks are assessed so that they can begin to take blood thinner to prevent complications & # 39; threatening."

The first author of the joint, Yanish Purmah, added: "An electrocardiogram (ECG), a test that measures the electrical activity & # 39; heart to show if you function with & # 39; normal mode or not, generally used to detects atrial fibrillation in patients.

"The choice of & # 39; ECGs requires a lot of resources and is a burden for the patient, therefore, it is important that appropriate patients selected for this type of & # 39; evaluation.

"The biomarkers that identified have the potential to be used in & # 39; blood test in & # 39; community environments, such practices & # 39; general practice, to tissimplifikaw selecting & # 39; patients for examination ECG. "

S & # 39; now, many studies have identified biomarkers in & # 39; & # 39 patients, atrial fibrillation were assumed and included analysis of & # 39; one or a small selection of & # 39; Blood biomarkers. F & # 39; this study, scientists analyzed 40 common cardiovascular biomarker in & # 39; of & # 39 Gort; 638 patients in the hospital were recruited between September 2014 and August 2016.

To achieve results, the scientists kkombinaw traditional statistical analysis with & # 39; & # 39 techniques; learning a completely new and innovative machines.

The main author, Dr. Larissa Fabritz, said: "The research results were surprising, although BNP already known biomarker and widely used in clinical practice, the results regarding the effectiveness of biomarker FGF-23 were finding unexpected and new, the -FGF 23 is currently used only on research-based environment, but we showed how its use can be invaluable in clinical settings. "

Ratios & # 39; the odds of model & # 39; logistic regression to predict atrial fibrillation (cohort & # 39; discovery). Three clinical risk factors (age, sex, and body mass index) and two biomarkers (growth factor mind and fibroblast 23) were associated with an increased risk of atrial fibrillation, while the ligand receptor 2 induced apoptosis of TNF related to biomarker was associated with a decrease in the odds of atrial fibrillation. Was found no significant interaction between age and sex. Error bars represented the interval & # 39; & # 39 confidence; 95%. BMI, the body mass index; BNP, brain peptide natriuretika; FGF-23, the fibroblast growth factor 23; TRAIL-R2 receptor ligand induced apoptosis related & # 39; TNF-2.

The corresponding author, the Paulus Kirchhof Professor, Director & # 39; the Institute of Cardiovascular Sciences at the University & # 39; Birmingham, said: "We hope that, as a result of our findings, more people will be diagnosed with & # 39; what often can & # 39; be silent disease to prevent any complication."

Comparing levels & # 39; biomarker between patients with and without atrial fibrillation. High levels of & # 39; natriuretiċi brain peptides and brain & # 39; factor & # 39; growth & # 39; fibroblasts observed in groups of 23 & # 39; atrial fibrillation in both cohorts discovery and validation. ** P?<?0.001; error bars represent the SEM. BNP, brain natriuretic peptide; FGF-23, fibroblast growth factor 23.

Funded by the University & # 39; Birmingham, research was supported by CATCH ME, a consortium funded by the European Union led by the University & # 39; Birmingham, the British Heart Foundation and Leducq Foundation.

The research was made & # 39; collaboration with & # 39; Sandwell and West Birmingham Hospitals Trust NHS, University Hospitals Birmingham NHS Foundation Trust, the European Society of Cardiology, The German Network fibrillation Atrjali (AFNET) and Health Data Research Research UK.

Professor Metin Avkiran, Medical Director Associate of the British Heart Foundation (BHF), added: "Atrial fibrillation increases the risk of & # 39; stroke, a serious condition that causes more than 36,000 deaths in the UK each year, but often is & # 39; often find too late

This research used sophisticated methods & # 39; machine learning and statistics to analyze patient data and provide encouraging evidence that a combination of & # 39; easy index to measure you & # 39; is used to predict atrial fibrillation.

"The study can & # 39; pave the way for better detection & # 39; persons with & # 39; F and their targeted treatment with & # 39; anticoagulant drugs to prevent & # 39; stroke and its devastating consequences. "

The research, which started in 2013, is ongoing and the next steps will include patient follow-up evaluations.

[ad_2]
Source link